Screening

Your daily dose of the clinical news you may have missed.

The USPSTF's revised CRC screening guidelines to include adults aged 45-49 years increased screening needs by about 23% without additional funding or resources for CHCs.

Your daily dose of the clinical news you may have missed.

A centralized mailed FIT outreach intervention significantly improved CRC screening in a diverse patient population, according to recent data

Find details on US colorectal cancer screening rates, dietary interventions for people with IBS, and research on the primary drivers of cost of IBD care.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

Your daily dose of the clinical news you may have missed.

William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.

William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.

Comments on the draft recommendation can be submitted through December 23, 2024.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

William Grady, MD, highlights the convenience and compliance of blood-based tests compared to colonoscopy and stool-based tests for colorectal cancer screening.

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.

Dermatologist Rebecca Hartman, MD, MPH, said that reliable point-of-care screening results can help reduce unnecessary specialist referral for benign lesions.

The DermaSensor skin cancer screening device was pitted against clinical impressions of lesions suspected with high confidence to be melanoma. Results, here.

Dermatologists at high volume dermatology centers referred suspicious lesions to pathology for biopsy and diagnosis. The results were compared with DermaSensor read-outs.

More than half of US adults who had a colonoscopy in past 5 years said they wish they knew more information before their first procedure.

Nearly 40% of adults aged 45 to 50 years completed a fecal immunochemical test within 3 months, according to a large retrospective study.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.

Your daily dose of the clinical news you may have missed.

After a false positive breast cancer screening result, women may be reluctant to participate in future screening, a topic that could benefit from the primary care touch.

Your daily dose of the clinical news you may have missed.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.